Role: Board Member

Rob is a partner at Telegraph Hill partners. He has worked in the area of securities law, corporate finance, venture capital and mergers & acquisitions since 1998.

Prior to joining THP, he worked in Citigroup Global Markets’ San Francisco office focused on healthcare investment banking and acquisition finance.  Previously, Rob worked at the Securities & Exchange Commission in Los Angeles and the New York-based law firm of Cravath, Swaine & Moore. Rob serves on several Boards on behalf of THP.  Rob received a BS in Geological Sciences and a BA in Economics from UCSB. He received a JD/MBA from Northwestern University School of Law and Kellogg School of Management.

Paul is a partner at Telegraph Hill partners.  Before joining THP, he was Head of Strategy and Corporate Development for Life Technologies in a number of key leadership positions. Dr. Grossman has led the acquisition or divestment of more than 25 businesses. Prior to joining Invitrogen, Dr. Grossman held a variety of leadership roles during his more than 20 years at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development.

Dr. Grossman received bachelors and Ph.D. degrees in chemical engineering from the University of California, Berkeley, a master’s degree in chemical engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law.

Deval has more than 20 years of experience helping to build and grow successful companies. He is currently a partner at Telegraph Hill Partner and serves on several boards. Prior to THP he was a founding Research Director at Synteni, which was acquired by Incyte Genomics.

Deval received a BA from the University of California, Berkeley and a PhD from Stanford University and currently serves on the Stanford Medical School Alumni Board of Governors.

Dan is currently a part-time Venture Partner at Decheng Capital and has been with the firm since July 2016. He serves on several Boards on behalf of Decheng Capital and as an Independent Director.

Prior to joining Decheng, Dr. Zabrowski worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals. Prior to joining Roche, Dr. Zabrowski worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago. Dr. Zabrowski received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.